NCT04851535已完成2 期
A Phase II Study To Evaluate The Efficacy And Safety of Jaktinib Hydrochloride Tablets In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Spleen Volume Response rate (SVRR) at Week 24
研究概览
简要总结
This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or refractory of ruxolitinib treatment.
详细描述
All subjects will receive a minimum of 6 treatment cycles or 24 weeks (a 28-day treatment cycle is defined as one treatment cycle).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects voluntarily sign the informed consent form (ICF);
- •Age ≥ 18 years, either male or female;
- •Subjects diagnosed with a PMF according to World Health Organization (WHO) criteria (2016 Edition), or patients diagnosed with a Post-PV-MF or Post-EF-MF according to International Working Group for Myeloproliferative Neoplasms Research and Treatment (2007 IWG-MRT) criteria;
- •Subjects with intermediate-2 or high-risk myelofibrosis, or Intermediate-1 myelofibrosis with symptoms according to the Dynamic International Prognostic System (DIPSS) scoring system;
- •Subjects are relapsed/refractory to Ruxolitinib:
- •Relapsed defined as Ruxolitinib treatment for ≥ 3 months, following an initial response, regrowth to < 10% spleen volume reduction (SVR) by MRI or < 30% decrease in spleen size by palpation from baseline;
- •Refractory defined as Ruxolitinib treatment for ≥ 3 months observed inadequate efficacy response: < 10%volume SVR by MRI or < 30% decrease in spleen size by palpation from baseline.
- •Subject has a measurable splenomegaly: spleen volume of ≥ 450 cm3 by MRI/CT and ≥ 5 cm below left costal margin by palpation spleen measuring;
- •Expected life expectancy is greater than 24 weeks;
- •Eastern Cooperative Oncology Group (ECOG) performance Score 0-2;
- •Laboratory examination within 7 days before the randomization, fulfilling the following criteria:
- •Neutrophil count ≥ 0.75 x 109/L, platelet count ≥ 75 x 109/L; Peripheral blood blasts ≤ 10%; ALT and AST≤ 3 ULN, DBIL ≤ 2.0 ULN; Serum creatinine ≤ 2.0 ULN.
排除标准
- •Subjects who have been previously exposed to Janus kinase (JAK) inhibitors other than Ruxolitinib for a total of> 2 weeks;
- •Subjects who have taken Ruxolitinib or other JAK inhibitor within 1 week prior to screening;
- •Subjects with any significant clinical and laboratory abnormalities which may affect the safety evaluation, such as uncontrolled diabetes, uncontrolled hypertension after taking two or more hypotensive drugs or peripheral neuropathy;
- •Subjects with congestive heart failure (NCI-CTCAE V5.0) Class II or above, uncontrolled or unstable angina or myocardial infarction, cerebrovascular accident, or pulmonary embolism within 6 months prior to screening;
- •Subjects who have a history of chronic or recurrent respiratory diseases, such as: chronic obstructive pulmonary disease, recurrent lung infections, etc., or have a history of lung infections within 3 months before screening, or currently have upper respiratory tract infections that have not recovered;
- •Subjects who have not fully recovered from surgical operation within 4 weeks prior to screening;
- •Subjects suffering from arrhythmia and requiring treatment, or QTcB > 480ms at screening;
- •Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal infections requiring treatment at screening;
- •Subjects who had undergone splenectomy, or received radiotherapy to the spleen within 6 months before screening;
- •Subjects with known human immunodeficiency virus (HIV), known active infectious Hepatitis B (HepB), and/or known active infectious Hepatitis C (HepC);
- •Female subjects who are pregnant, currently breastfeeding, planning to become pregnant;
- •Subjects who had experienced malignant tumors (except for adequately treated local basal cell or squamous cell carcinoma of the skin and cervical carcinoma in situ that have been cured) or in combination with other serious diseases within the past 5 years;
- •Subjects who have participated in another clinical trial of a new drug or medical instrument within 1 month before screening.
- •Subjects who have any other conditions that are not specified in the protocol but the investigator believes that they are not suitable for inclusion in this trial.
研究组 & 干预措施
Jaktinib 100mg Bid
Experimental
Jaktinib twice daily for 6 consecutive 28-day cycles, orally, empty stomach
干预措施: Jaktinib Hydrochloride Tablets (Drug)
结局指标
主要结局
Spleen Volume Response rate (SVRR) at Week 24
时间窗: at Week 24
The proportion of subjects with spleen volume reduction from baseline ≥ 35% measured by MRI or CT.
次要结局
- Clinical Objective Response Rate (complete remission (CR) + partial remission (PR))(Baseline, up to Year 2)
- Spleen Response(up to Year 2)
- Anemia Response(up to Year 2)
- Response rate of MF-related symptoms(Baseline, up to Year 2)
- Progression free survival (PFS)(From the date of first dose to the earliest date of either increase in spleen volume ≥ 25% from on-study nadir or death, up to Year 2)
- Leukemia free survival (LFS)(From the date of first dose to the earliest date of either leukemia or death, up to Year 2)
- Overall survival (OS)(From the date of first dose to the date of death, up to Year 2)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian CancerOvarian CancerNCT04089189Impact Therapeutics, Inc.93
已完成
2 期
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular CarcinomaHepatocellular CarcinomaNCT05864105Biotheus Inc.35
招募中
2 期
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular CarcinomaHepatocellular CarcinomaNCT05304481Lukas Biomedical Inc.95
撤回
2 期
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisRelapsing Multiple SclerosisNCT05496894CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
终止
2 期
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary MyelofibrosisNCT03627403University of Utah17